美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

AdvisorShares Psychedelics ETF

24.87

-0.2800-1.11%

盤後：24.870.00000.00%16:10 EDT

成交量：2.30萬

成交額：57.61萬

市值：5,769.78萬

市盈率：- -

高：25.58

開：25.53

低：24.67

收：25.15

52周最高：27.02

52周最低：15.63

股本：232.00萬

流通股本：232.00萬

量比：0.72

換手率：0.99%

股息：1.71

股息率：6.86%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Compass Pathways在2026年精神病學大會上於美國啓動‘改變難治性抑鬱症的旋律’項目，深化醫療專業人士認知

專家敦促美國食品藥品監督管理局（FDA）為迷幻藥物制定明確的安全和獲取標準

Compass Pathways公布美國資助計劃入選者，旨在推進Comp360獲批後供應商培訓項目

Compass Pathways 25毫克組在第52周實現MADRS平均降低13點，療效持續至一年

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/PSIL"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.87,"timestamp":1789761600000,"preClose":25.15,"halted":0,"volume":23016,"hourTrading":{"tag":"盘后","latestPrice":24.87,"preClose":24.87,"latestTime":"16:10 EDT","volume":11,"amount":273.57,"timestamp":1789762204628,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011133200795228533,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"盤後交易","change":-0.28,"latestTime":"09-18 17:26:36 EDT","open":25.53,"high":25.58,"low":24.67,"amount":576066,"amplitude":0.036183,"askPrice":25.17,"askSize":30,"bidPrice":22.68,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789776000000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":25.15,"sharesOutstanding":1184976,"nav":24.367,"aum":56531795.79,"dividendRate":0.068565,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":25.86,"preClose":25.15,"latestTime":"09:17 EDT","volume":28,"amount":719.9700200000001,"timestamp":1789737431335,"change":0.71,"changeRate":0.028231,"amplitude":0.020278},"postHourTrading":{"tag":"盘后","latestPrice":24.87,"preClose":24.87,"latestTime":"16:10 EDT","volume":11,"amount":273.57,"timestamp":1789762204628,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.719574,"impliedVol":0.3416,"impliedVolPercentile":0.4661},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.719574,"shares":2319976,"dividePrice":1.7052,"high":25.58,"amplitude":0.036183,"preClose":25.15,"low":24.67,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.87,"committee":0.538462,"eps":0,"divideRate":0.068565,"volume":23016,"delay":0,"ttmEps":0,"open":25.53,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.7682,"twentyDayClose":25.95,"sixtyDayClose":21.7221},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1111501056","title":"Compass Pathways在2026年精神病學大會上於美國啓動‘改變難治性抑鬱症的旋律’項目，深化醫療專業人士認知","url":"https://stock-news.laohu8.com/highlight/detail?id=1111501056","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111501056?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 18:31","pubTimestamp":1789468272,"startTime":"0","endTime":"0","summary":"在即将召开的2026年精神病学大会上，COMPASS Pathways plc正式宣布于美国市场推出全新倡议——“改变难治性抑郁症的旋律”。该项目的核心目标在于拓宽医疗保健专业人士对难治性抑郁症的理解边界，推动临床认知的迭代升级。在2026年精神病学大会这一汇聚全球精神健康领域顶尖专家的平台上，该项目无疑将占据重要位置。COMPASS Pathways此举，也标志着其在推动精神健康治疗创新道路上迈出了坚实一步，超越了药物研发本身，深入到医疗生态系统的神经中枢。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667962699","title":"專家敦促美國食品藥品監督管理局（FDA）為迷幻藥物制定明確的安全和獲取標準","url":"https://stock-news.laohu8.com/highlight/detail?id=2667962699","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667962699?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 06:39","pubTimestamp":1789425555,"startTime":"0","endTime":"0","summary":"此次听证会是美国总统唐纳德·特朗普政府自4月  以来，为推动合格的迷幻药物项目  进入市场所开展的、历时数月的最新举措。发言者敦促研究人员收集有关月经周期、妊娠及产后状况、围绝经期、绝经期、激素水平及合并用药的数据，并警告称汇总结果可能会掩盖疗效或不良事件方面的差异。“FDA对安全性和有效性的评估……必须始终是未来任何临床应用的基础，”美国精神病学协会表示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4S4561NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","PSIL","BK4007","DFTX","BK4139","GHRS","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100081863","title":"Compass Pathways公布美國資助計劃入選者，旨在推進Comp360獲批後供應商培訓項目","url":"https://stock-news.laohu8.com/highlight/detail?id=1100081863","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100081863?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:36","pubTimestamp":1789036568,"startTime":"0","endTime":"0","summary":"Compass Pathways正式揭晓了美国资助计划的获选名单。这项计划聚焦于Comp360产品在获得监管批准之后的供应商培训事宜。通过这一举措，公司希望为相关培训体系的搭建提供有力支持。入选的机构将在后续阶段发挥关键作用，协助推动培训内容的开发与实施。此次公布的名单标志着该计划进入实质性推进阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168737220","title":"Compass Pathways 25毫克組在第52周實現MADRS平均降低13點，療效持續至一年","url":"https://stock-news.laohu8.com/highlight/detail?id=1168737220","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168737220?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:36","pubTimestamp":1788950183,"startTime":"0","endTime":"0","summary":"Compass Pathways的25毫克剂量组在第52周呈现出平均13分的MADRS评分降幅，且这一改善效果能够稳定维持长达一年之久。这一结果不仅彰显了治疗方案的持续有效性，也为其在长期临床应用中提供了有力佐证。疗效的持久性无疑成为该研究中最引人瞩目的亮点之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PSIL\",params:#limit:6,delay:false,,,undefined,":[]}}